Categories Earnings, Energy

ExxonMobil (XOM) slips to a loss in Q1 but beats estimates

ExxonMobil (NYSE: XOM) reported its financial results for the quarter ended March 31, 2020, on Friday. Despite the impact of the COVID-19 pandemic on the global markets, the results exceeded analysts’ expectations.

ExxonMobil slipped to a loss in the first quarter of 2020 from a profit last year due to the inclusion of a charge from market-related write-downs. This reflected non-cash inventory valuation impacts from lower commodity prices and asset impairments.

ExxonMobil (XOM) Q1 2020 earnings review

The company said the COVID-19 has significantly impacted near-term demand, resulting in oversupplied markets and unprecedented pressure on commodity prices and margins. ExxonMobil’s capital allocation priorities remain unchanged. The company’s objective is to continue investing in industry-advantaged projects to create value, preserve cash for the dividend, and make appropriate use of its balance sheet.

In response to market conditions, ExxonMobil is lowering 2020 capital spending by 30% and cash operating expenses by 15%. Capex is now expected to be about $23 billion for the year, down from the previously announced guidance of $33 billion.

Past Performance

Also Read:  Qualcomm (QCOM) stock gains on Q3 earnings beat; clinches patent deal with Huawei

Most Popular

Baidu (BIDU) Q2 earnings rise unexpectedly; stock falls

https://www.youtube.com/watch?v=50yUaLybUnA&t=667s China-based internet search firm Baidu Inc. (NASDAQ: BIDU) reported financial results for the second quarter of 2020 on Thursday after the market's close. Earnings exceeded analysts’ expectations, but the

Applied Materials (AMAT) tops Q3 2020 targets; provides Q4 outlook

Applied Materials' (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market's views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%,

Is Altimmune (ALT) stock a buy right now?

A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or in the treatment of COVID-19. While these companies

Top